EA201491711A1 - Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов - Google Patents

Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов

Info

Publication number
EA201491711A1
EA201491711A1 EA201491711A EA201491711A EA201491711A1 EA 201491711 A1 EA201491711 A1 EA 201491711A1 EA 201491711 A EA201491711 A EA 201491711A EA 201491711 A EA201491711 A EA 201491711A EA 201491711 A1 EA201491711 A1 EA 201491711A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nonlinear
conjugates
drug
diseases
active agents
Prior art date
Application number
EA201491711A
Other languages
English (en)
Other versions
EA030318B1 (ru
Inventor
Цзе Фу
Питер Энтони Кампочиаро
Джастин Скот Хэйнс
Original Assignee
Дзе Джонс Хопкинс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Джонс Хопкинс Юниверсити filed Critical Дзе Джонс Хопкинс Юниверсити
Publication of EA201491711A1 publication Critical patent/EA201491711A1/ru
Publication of EA030318B1 publication Critical patent/EA030318B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Представлены конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для лечения и профилактики заболеваний и нарушений работы глаза. Конъюгаты полимера с лекарственным средством могут образовывать наночастицы, микрочастицы и импланты, которые способны эффективно доставлять терапевтические уровни одного или более активных агентов в течение пролонгированного периода времени. Введение в глаз активного агента в форме конъюгата нелинейного мультиблочного сополимера с лекарственным средством уменьшает побочные эффекты по сравнению с введением одного активного агента. Также представлены способы лечения интраокулярных неоваскулярных заболеваний, таких как влажная возрастная макулярная дегенерация, а также заболеваний и нарушений работы глаза, ассоциированных с воспалением, таких как увеит.
EA201491711A 2012-03-16 2013-03-12 Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов EA030318B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611975P 2012-03-16 2012-03-16
PCT/US2013/030536 WO2013138346A1 (en) 2012-03-16 2013-03-12 Non-linear multiblock copolymer-drug conjugates for the delivery of active agents

Publications (2)

Publication Number Publication Date
EA201491711A1 true EA201491711A1 (ru) 2015-03-31
EA030318B1 EA030318B1 (ru) 2018-07-31

Family

ID=47997897

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491711A EA030318B1 (ru) 2012-03-16 2013-03-12 Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов

Country Status (9)

Country Link
US (4) US10159743B2 (ru)
EP (1) EP2825207B1 (ru)
JP (2) JP6138904B2 (ru)
CN (1) CN104394891B (ru)
AU (1) AU2013232300B2 (ru)
CA (1) CA2867203C (ru)
EA (1) EA030318B1 (ru)
HK (1) HK1206268A1 (ru)
WO (1) WO2013138346A1 (ru)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9730790B2 (en) 2009-09-29 2017-08-15 Edwards Lifesciences Cardiaq Llc Replacement valve and method
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
ES2737960T3 (es) 2010-10-01 2020-01-17 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (en) 2011-10-03 2021-12-01 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
EA032552B1 (ru) 2012-03-16 2019-06-28 Дзе Джонс Хопкинс Юниверсити Препараты с контролируемым высвобождением для доставки ингибиторов hif-1
EA030318B1 (ru) * 2012-03-16 2018-07-31 Дзе Джонс Хопкинс Юниверсити Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6360040B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法
AU2013256008B2 (en) 2012-05-04 2016-02-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9681951B2 (en) 2013-03-14 2017-06-20 Edwards Lifesciences Cardiaq Llc Prosthesis with outer skirt and anchors
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR102307175B1 (ko) 2013-09-16 2021-10-01 아스트라제네카 아베 치료용 중합체 나노입자 및 이의 제조 방법과 사용 방법
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015152117A1 (ja) * 2014-03-31 2015-10-08 千寿製薬株式会社 アルキニルインダゾール誘導体及びその用途
RU2729731C2 (ru) 2014-12-15 2020-08-11 Зе Джонс Хопкинс Юниверсити Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний
WO2016118506A1 (en) * 2015-01-20 2016-07-28 The Johns Hopkins University Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
MX2018003462A (es) 2015-09-22 2018-09-06 Graybug Vision Inc Compuestos y composiciones para el tratamiento de trastornos oculares.
SG11201803663XA (en) 2015-11-12 2018-05-30 Graybug Vision Inc Aggregating microparticles for therapy
WO2017151879A1 (en) * 2016-03-02 2017-09-08 The Johns Hopkins University Compositions for sustained release of anti-glaucoma agents to control intraocular pressure
WO2018005552A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
ES2910987T3 (es) * 2016-08-09 2022-05-17 Univ Liverpool Composiciones oftálmicas
BR112019019452A2 (pt) 2017-03-23 2020-04-14 Graybug Vision Inc composto, e, uso de um composto
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
EP3654950A4 (en) * 2017-07-17 2021-04-21 Wolfcreek Biotech Pte Ltd MICROPARTICLE FORMULATIONS FOR THE DELIVERY OF ACTIVE INGREDIENTS
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
EP3866773A4 (en) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL CONDITIONS
CA3178820A1 (en) * 2020-05-29 2021-12-02 The Regents Of The University Of California Compositions and methods for enhancing visual function
CN115364199A (zh) * 2021-05-19 2022-11-22 远大医药（中国）有限公司 包含pedf衍生的短肽的组合物及其制备方法和用途

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US159743A (en) * 1875-02-16 Improvement in horseshoe-machines
GB929401A (en) 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
GB929405A (en) 1958-12-22 1963-06-19 Upjohn Co Processes for the encapsulation of particles
GB969808A (en) 1962-06-08 1964-09-16 Boots Pure Drug Co Ltd Anthelmintic compositions and compounds
US4027676A (en) 1975-01-07 1977-06-07 Ethicon, Inc. Coated sutures
US4201216A (en) 1976-12-15 1980-05-06 Ethicon, Inc. Absorbable coating composition for sutures
IT1148784B (it) 1980-04-09 1986-12-03 Eurand Spa Procedimento per la preparazione di microcapsule in un veicolo liquido
US4888176A (en) 1984-05-21 1989-12-19 Massachusetts Institute Of Technology Controlled drug delivery high molecular weight polyanhydrides
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4857602A (en) 1986-09-05 1989-08-15 American Cyanamid Company Bioabsorbable surgical suture coating
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
JP2517760B2 (ja) 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US4994074A (en) 1990-02-01 1991-02-19 Ethicon, Inc. Copolymers of ε-caprolactone, glycolide and glycolic acid for suture coatings
US5196522A (en) 1990-11-01 1993-03-23 Board Of Regents, The University Of Texas System Anthracycline analogues bearing latent alkylating substituents
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5696298A (en) 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
DE69329594T2 (de) 1992-02-28 2001-05-31 Univ Texas Photopolymerinierbare, biologisch abbaubare hydrogele als gewebekontaktmaterialien und trägerstoffe für kontrollierte freisetzung
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
JPH09504308A (ja) * 1993-07-23 1997-04-28 マサチューセッツ インスティチュート オブ テクノロジー 非直鎖状の親水性−疎水性マルチブロックコポリマーのナノ粒子およびマイクロ粒子
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5522842A (en) 1994-03-11 1996-06-04 Poly-Med, Inc. Absorbable Ε-caprolactone polymers as suture coatings displaying auto catalyzed hydrolysis
US6007845A (en) * 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US5628981A (en) 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
DE69533615T2 (de) 1995-06-27 2005-10-13 Pharmachemie B.V. Anthracyclin Prodrugs, Verfahren zu deren Herstellung und deren Verwendung in der selektiven Chemotherapie
US5756652A (en) 1996-02-29 1998-05-26 Depuy Orthopaedics, Inc. Poly (ester-anhydrides) and intermediates therefor
US5869130A (en) 1997-06-12 1999-02-09 Mac Dermid, Incorporated Process for improving the adhesion of polymeric materials to metal surfaces
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
JP4130305B2 (ja) * 1997-09-10 2008-08-06 ラトガーズ，ザ ステート ユニバーシティー オブ ニュージャージー 治療的に有用な分解産物を有するポリアンヒドリド
US6174524B1 (en) * 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6235869B1 (en) 1998-10-20 2001-05-22 United States Surgical Corporation Absorbable polymers and surgical articles fabricated therefrom
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US20040258763A1 (en) 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US20060194008A1 (en) 1999-09-22 2006-08-31 Princeton University Devices with multiple surface functionality
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2002013701A1 (en) 2000-08-17 2002-02-21 Tyco Healthcare Group Lp Sutures and coatings made from therapeutic absorbable glass
ES2382636T3 (es) 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Método para producir composiciones para la administración mejorada de moléculas bioactivas
JP5054274B2 (ja) 2000-11-01 2012-10-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼の疾患を治療するための方法および組成物
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
CA2437555A1 (en) 2001-02-01 2002-08-08 Yiyu Zou Stabilised polymeric aerosols for pulmonary gene delivery
US6932894B2 (en) 2001-05-15 2005-08-23 Therasense, Inc. Biosensor membranes composed of polymers containing heterocyclic nitrogens
EP1411926B1 (en) 2001-08-01 2005-06-01 MERCK PATENT GmbH Integrin inhibitors for the treatment of eye diseases
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
DE10146264A1 (de) 2001-09-20 2003-04-17 Ecolab Gmbh & Co Ohg Verwendung von O/W-Emulsionen zur Kettenschmierung
AU2003248624B2 (en) 2002-06-05 2006-04-06 University Of Florida Opthalmic drug delivery system
US7122189B2 (en) * 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
EP1581245A2 (en) 2002-12-17 2005-10-05 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
WO2004060977A1 (en) 2002-12-30 2004-07-22 Nektar Therapeutics Al, Corporation Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles
EP1587534A1 (en) 2003-01-17 2005-10-26 Children's Hospital Medical Center Use of tff2, or agents inducing tff2, in the therapy of allergies
US20050009910A1 (en) 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
GB0328630D0 (en) 2003-12-10 2004-01-14 Medpharm Ltd Metered dose inhalation preparations
US7357810B2 (en) 2003-12-18 2008-04-15 Ethicon, Inc. High strength suture with absorbable core and suture anchor combination
US7329271B2 (en) 2003-12-18 2008-02-12 Ethicon, Inc. High strength suture with absorbable core
BRPI0418330A (pt) 2003-12-31 2007-05-02 Pfizer Prod Inc composições sólidas de drogas de solubilidade baixa e poloxámeros
WO2005072710A2 (en) 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
EP1711510A4 (en) 2004-02-05 2008-11-26 Intradigm Corp THERAPY WITH RNAI AGENTS APPLIED IN THE TREATMENT OF OCULAR DISEASES RESULTING FROM NEOVASCULARIZATION
WO2005117938A2 (en) 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
WO2006083260A2 (en) 2004-04-28 2006-08-10 Angiotech Biomaterials Corporation Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
JP2008512350A (ja) 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
EP1771213B1 (en) 2004-07-27 2010-04-28 DSM IP Assets B.V. Elongated surgical repair product based on uhmwpe filaments
CA2590098C (en) 2004-12-10 2015-03-31 Justin Hanes Functionalized poly (ether-anhydride) block copolymers
EP1874267A1 (en) 2005-04-13 2008-01-09 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
DE102005023993A1 (de) 2005-05-20 2006-11-23 TransMIT Gesellschaft für Technologietransfer mbH Nicht virales Vektorsystem zum Transport von Nukleinsäure in die Lunge
EP1912676A2 (en) * 2005-07-28 2008-04-23 (Osi) Eyetech, Inc. Cyclitol linker polymer conjugate
WO2007025169A2 (en) 2005-08-25 2007-03-01 Emory University Hif inhibitors
US20070071756A1 (en) 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an agent to ameliorate inflammation
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US7752607B2 (en) 2005-10-13 2010-07-06 Sap Ag System and method for testing business process configurations
US20070093461A1 (en) 2005-10-26 2007-04-26 Bausch & Lomb Incorporated Effect of Loteprednol etabonate on vascular dysfunction
WO2007076358A1 (en) 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2007133812A2 (en) 2005-12-30 2007-11-22 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
CA2636716C (en) 2006-01-13 2014-12-23 Surmodics, Inc. Microparticle containing matrices for drug delivery
CA2632871A1 (en) 2006-01-30 2007-08-09 Angiotech Pharmaceuticals, Inc. Sutures and fibrosing agents
EP1818348A1 (en) 2006-02-10 2007-08-15 Mnemoscience GmbH Polymer material for useful medical devices
US20070231360A1 (en) 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20080166411A1 (en) 2006-04-10 2008-07-10 Pfizer Inc Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
US20070249536A1 (en) * 2006-04-25 2007-10-25 Ma Peter X Three-component polyanhydride copolymers and a method of forming the same
JP2009537662A (ja) 2006-05-15 2009-10-29 タイコ ヘルスケア グループ リミテッド パートナーシップ ハロゲン化環状ラクトンおよびハロゲン化環状ラクトンから製造されるポリマー
KR100787131B1 (ko) 2006-07-04 2007-12-21 한국생명공학연구원 Ｈｉｆ―１ 활성을 저해하는 화합물, 이의 제조방법 및이를 유효성분으로 함유하는 약학적 조성물
US20100034749A1 (en) 2006-07-10 2010-02-11 Medigene Ag Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases
AU2007277035A1 (en) 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic light toxicity
DE602007012559D1 (de) 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
WO2008033924A2 (en) * 2006-09-12 2008-03-20 Board Of Regents Of The University Of Nebraska Methods and compositions for targeted delivery of therapeutic agents
US8394488B2 (en) * 2006-10-06 2013-03-12 Cordis Corporation Bioabsorbable device having composite structure for accelerating degradation
AR063621A1 (es) 2006-11-09 2009-02-04 Alcon Res Ltd Matriz polimerica insoluble en agua para la administracion de farmacos
US8309222B2 (en) 2007-04-25 2012-11-13 Covidien Lp Coated filaments
WO2008137066A1 (en) 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
US20080287341A1 (en) 2007-05-18 2008-11-20 Danyang Chen Treatment of vascular abnormalities using nanoparticles
WO2009003110A2 (en) * 2007-06-26 2008-12-31 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
US8217134B2 (en) 2007-08-30 2012-07-10 Bezwada Biomedical, Llc Controlled release of biologically active compounds
US8703119B2 (en) 2007-10-05 2014-04-22 Polygene Ltd. Injectable biodegradable polymer compositions for soft tissue repair and augmentation
EP2195033A1 (en) 2007-10-08 2010-06-16 Fovea Pharmaceuticals SA Aqueous ophthalmic formulations
US20090203709A1 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
US20090226531A1 (en) 2008-03-07 2009-09-10 Allergan, Inc. Methods and composition for intraocular delivery of therapeutic sirna
CN101977631A (zh) * 2008-03-18 2011-02-16 日本化药株式会社 生理活性物质的高分子量偶联物
EP2355853B1 (en) 2008-10-10 2016-12-07 Polyactiva Pty Ltd Biodegradable polymer - bioactive moiety conjugates
US20100094340A1 (en) 2008-10-15 2010-04-15 Tyco Healthcare Group Lp Coating compositions
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100152831A1 (en) 2008-12-12 2010-06-17 Medtronic Vascular, Inc. Implantable Medical Devices Having Multiblock Copolymers
WO2010091187A2 (en) 2009-02-04 2010-08-12 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
US8062653B2 (en) 2009-02-18 2011-11-22 Bezwada Biomedical, Llc Controlled release of nitric oxide and drugs from functionalized macromers and oligomers
BRPI1012302A2 (pt) 2009-03-03 2015-09-22 Alcon Res Ltd composição farmacêutica para a liberação de compostos de inibição de tirosina quinase receptora (rtki) para o olho
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
US20110262490A1 (en) * 2009-03-30 2011-10-27 Jerry Zhang Polymer-agent conjugates, particles, compositions, and related methods of use
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
CN101684177A (zh) * 2009-05-27 2010-03-31 沈阳药科大学 叶酸偶联聚乙二醇聚烷基氰基丙烯酸酯及制法和应用
CN106139123A (zh) 2009-08-05 2016-11-23 爱力根公司 脂质运载蛋白突变蛋白的控制释放制剂
CA2781107C (en) 2009-11-16 2019-01-22 Angiotech Pharmaceuticals, Inc. Braided self-retaining sutures and methods
EP2335686A1 (en) 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
GB0922624D0 (en) 2009-12-24 2010-02-10 Croda Int Plc Inverse emulsions
NL2004047C2 (en) 2010-01-04 2011-07-05 D O R C Dutch Ophthalmic Res Ct International B V An ophthalmic surgical device and a method of performing ophthalmic surgery.
WO2011095203A1 (en) 2010-02-02 2011-08-11 Medovent Gmbh Chitosan fiber
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT
US20130071349A1 (en) 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP2635254B1 (en) 2010-11-05 2019-05-15 The John Hopkins University Compositions and methods relating to reduced mucoadhesion
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
RU2659454C2 (ru) 2011-03-23 2018-07-02 ЭТИКОН ЭлЭлСи Самоудерживающиеся нити с регулируемой петлей
JP5973547B2 (ja) 2011-03-29 2016-08-23 サン・ケミカル・ベスローテン・ベンノートシャップ ポリウレタンを含む２コートバリア系
CA2859046C (en) 2011-12-14 2019-10-22 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
US20130217657A1 (en) 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
RU2598627C2 (ru) 2012-01-19 2016-09-27 Дзе Джонс Хопкинс Юниверсити Композиции на основе наночастиц с улучшенным проникновением через слизистые оболочки
EA030318B1 (ru) * 2012-03-16 2018-07-31 Дзе Джонс Хопкинс Юниверсити Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов
EA032552B1 (ru) 2012-03-16 2019-06-28 Дзе Джонс Хопкинс Юниверсити Препараты с контролируемым высвобождением для доставки ингибиторов hif-1
US20140107025A1 (en) 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
NZ700875A (en) 2012-05-03 2017-03-31 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
JP6360040B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法
AU2013256008B2 (en) 2012-05-04 2016-02-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
MX363147B (es) 2012-09-17 2019-03-11 Pfizer Inc Star Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos para realizarlas y usarlas.
BR112015006087A2 (pt) 2012-09-20 2017-07-04 Akina Inc microcápsulas biodegradáveis contendo material de enchimento
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
ES2834964T3 (es) 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
WO2016118506A1 (en) 2015-01-20 2016-07-28 The Johns Hopkins University Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure

Also Published As

Publication number Publication date
JP6371438B2 (ja) 2018-08-08
JP6138904B2 (ja) 2017-05-31
EA030318B1 (ru) 2018-07-31
WO2013138346A1 (en) 2013-09-19
CN104394891B (zh) 2019-04-16
US11660349B2 (en) 2023-05-30
CA2867203C (en) 2016-09-20
US20210177979A1 (en) 2021-06-17
AU2013232300A1 (en) 2014-10-02
EP2825207B1 (en) 2020-08-19
US20230364247A1 (en) 2023-11-16
EP2825207A1 (en) 2015-01-21
CN104394891A (zh) 2015-03-04
US10933144B2 (en) 2021-03-02
HK1206268A1 (en) 2016-01-08
AU2013232300B2 (en) 2015-12-17
JP2017125075A (ja) 2017-07-20
CA2867203A1 (en) 2013-09-19
JP2015509986A (ja) 2015-04-02
US10159743B2 (en) 2018-12-25
US20130272994A1 (en) 2013-10-17
US20190070302A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
EA201491711A1 (ru) Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов
PH12017501097A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
EA201590902A1 (ru) Способы и устройства, применяемые для лечения глазных болезней у человека
MX2010003774A (es) Formulaciones oftalmicas acuosas.
MX2021006092A (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
EA201491710A1 (ru) Препараты с контролируемым высвобождением для доставки ингибиторов hif-1
GB2438544A (en) Liquid formulations for treatment of diseases or conditions
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
MX361520B (es) Composiciones y métodos para tratar edema ocular, neovascularización y enfermedades relacionadas.
WO2011084366A3 (en) Compositions and drug delivery systems for intraocular delivery of sirna molecules, their use for treating conditions
MX2020005217A (es) Composicion oftalmica y dispositivo de administracion de la misma.
NZ704247A (en) Compositions and treatment for eye diseases and disorders
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
WO2008154482A3 (en) Sirna compositions and methods of use in treatment of ocular diseases
EP4124346A3 (en) Compositions and methods for treating diseases
EP4324454A3 (en) Cross-linking agents and associated methods
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
PH12017502155A1 (en) Formation of cyclosporin a/cyclodextrin nanoparticles
IN2014CN02972A (ru)
WO2015094019A3 (ru) Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
WO2015048188A8 (en) Modified fibroblast growth factors for the treatment of ocular disorders
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
MX2022002306A (es) Metodos de tratamiento de enfermedades oculares con un implante para la administracion sostenida de farmacos.
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment